Medical condition
Hiv
Hiv is a medical condition tracked by NovaPharmaNews across 12 associated drugs and ongoing industry coverage. Explore approved and pipeline therapies, regulatory status, and the latest developments.
Associated drugs & therapies
- dolutegravir (TIVICAY) Antiinfectives for systemic use (J05)
- emtricitabine (DESCOVY) Antiinfectives for systemic use (J05)
- nevirapine (NEVIRAPINE VIATRIS) Antiinfectives for systemic use (J05)
- lamivudine (3TC) Antiinfectives for systemic use (J05)
- atazanavir sulfate (REYATAZ) Antiinfectives for systemic use (J05)
- ritonavir (NORVIR) Antiinfectives for systemic use (J05)
- darunavir (DARUNAVIR JUNO) Antiinfectives for systemic use (J05)
- etravirine (INTELENCE) Antiinfectives for systemic use (J05)
- filgrastim (NIVESTIM) Antineoplastic and immunomodulating agents (L03)
- efavirenz (EFAVIRENZ TEVA) Antiinfectives for systemic use (J05)
- abacavir (ZIAGEN) Antiinfectives for systemic use (J05)
- enfuvirtide (FUZEON) Antiinfectives for systemic use (J05)
Clinical pipeline & programs
Explore Infectious disease drug development programs tracked across clinical phases.
Latest Hiv news
Merck and Gilead report mixed outcomes in lung cancer and HIV studies
Merck Gilead report mixed outcomes in key lung cancer and HIV studies: a Phase 3 Trodelvy plus KEYTRUDA lung cancer trial was halted, while two Phase 3 HIV studies for islatravir/lenacapavir reported positive topline results. This plan focuses on the business and clinical implications for analysts and BD teams.
Lenacapavir posts 100% HIV prevention in PURPOSE 1
Gilead’s lenacapavir posted 100% efficacy in the Phase 3 PURPOSE 1 trial for HIV prevention in cisgender women. The result strengthens the case for Lenacapavir PrEP and raises the stakes for Gilead’s next regulatory and clinical catalysts.
Scientists uncover new hiding spot for HIV in marrow
A team led by virologist Kathleen Collins at the University of Michigan has discovered that HIV can hide inside bone marrow cells, revealing a previously unknown reservoir. This finding challenges current cure strategies and opens new avenues for therapeutic targeting.
HIV Treatment Clinical Trials Africa: Long-Acting Injectables & AMA Pathways
This article delves into HIV treatment clinical trials in Africa, highlighting long-acting injectables and the AMA pathways for enhanced patient care.
FDA Grants Priority Review for Gilead's Bictegravir Plus Lenacapavir HIV Treatment Combination
Gilead Sciences receives FDA priority review for novel once-daily HIV treatment combining bictegravir and lenacapavir, potentially the smallest single-tablet regimen.
FDA Approves Merck's IDVYNSO: First Non-INSTI, Tenofovir-Free Two-Drug HIV Treatment
FDA approves Merck's IDVYNSO (doravirine/islatravir), the first non-INSTI, tenofovir-free two-drug HIV regimen showing non-inferior efficacy to BIKTARVY.
SAHPRA HIV treatment approval: Lenacapavir's Role in Epidemic Control
SAHPRA's recent approval of Lenacapavir marks a significant advancement in HIV treatment, offering new hope for epidemic control and patient care.
SAHPRA Approval of Lenacapavir: A New Era in HIV Prevention in South Africa
Lenacapavir has received SAHPRA approval, heralding a new era in HIV prevention in South Africa and offering hope for those at risk.